Reviewer's report
Title:Candidiasis and other oral mucosal lesions during and after interferon
therapy for HCV-related chronic liver diseases
Version: 3Date:23 July 2012
Reviewer: Alessio Aghemo
Reviewer's report:
Major Compulsory Revisions
The Authors keep referring to anti-HCV therapy as IFN therapy, but de facto
patients were treated with PegIFN plus ribavirin. There are small papers showng
Ribavirin to cause salivary gland ipairment (Aghemo et al Hepatitis Monthly
2011), hence the authors should comment prvious findings and change all the
manuscript referring also to Ribavirin as a potential cause of orla lesions.
I would like to have more data on salivary flow during treatment and follow-up.
Did they return to normal in the follow-up? I would add this data in the results
section
Were salivary flow rates associated with oral lesions at baseline or on tx?
Minor essential revisions
How was Sjogren excluded? Were all patients tested for auto-antibodies at
baseline? This needs to be specified
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
'I declare that I have no competing interests
Reviewer's report
Title:Candidiasis and other oral mucosal lesions during and after interferon
therapy for HCV-related chronic liver diseases
Version: 3Date:23 July 2012
Reviewer: Alessio Aghemo
Reviewer's report:
Major Compulsory Revisions
The Authors keep referring to anti-HCV therapy as IFN therapy, but de facto
patients were treated with PegIFN plus ribavirin. There are small papers showng
Ribavirin to cause salivary gland ipairment (Aghemo et al Hepatitis Monthly
2011), hence the authors should comment prvious findings and change all the
manuscript referring also to Ribavirin as a potential cause of orla lesions.
I would like to have more data on salivary flow during treatment and follow-up.
Did they return to normal in the follow-up? I would add this data in the results
section
Were salivary flow rates associated with oral lesions at baseline or on tx?
Minor essential revisions
How was Sjogren excluded? Were all patients tested for auto-antibodies at
baseline? This needs to be specified
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
'I declare that I have no competing interests
Please review this paper.
user
Reviewer's report
Title:Candidiasis and other oral mucosal lesions during and after interferon
therapy for HCV-related chronic liver diseases
Version: 3Date:23 July 2012
Reviewer: Alessio Aghemo
Reviewer's report:
Major Compulsory Revisions
The Authors keep referring to anti-HCV therapy as IFN therapy, but de facto
patients were treated with PegIFN plus ribavirin. There are small papers showng
Ribavirin to cause salivary gland ipairment (Aghemo et al Hepatitis Monthly
2011), hence the authors should comment prvious findings and change all the
manuscript referring also to Ribavirin as a potential cause of orla lesions.
I would like to have more data on salivary flow during treatment and follow-up.
Did they return to normal in the follow-up? I would add this data in the results
section
Were salivary flow rates associated with oral lesions at baseline or on tx?
Minor essential revisions
How was Sjogren excluded? Were all patients tested for auto-antibodies at
baseline? This needs to be specified
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
'I declare that I have no competing interests
assistant